Therapeutic progress in castration-resistant prostate cancer
10.3760/cma.j.issn.1006-9801.2012.04.024
- VernacularTitle:去势抵抗性前列腺癌治疗新进展
- Author:
Lu HAN
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Androgen antagonists;
Immunotherapy;
Reaptor,endothelin A;
Treatment outcome
- From:
Cancer Research and Clinic
2012;24(4):282-285
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer represents one of the most common cancer in men, and the treatment of castrate refractory prostate cancer (CRPC) is still a challenge in the clinical practice,as there are few effective therapies to lengthen patients life.Nowadays,with the expansion of knowledge regarding the biology of CRPC,many novel approaches which are currently in development yielded promising results in the clinical setting for patients.
